Allergan PLC (AGN)

Statement of Financial Position, Liabilities and Stockholders’ Equity

Difficulty: Beginner

The statement of financial position provides creditors, investors, and analysts with information on company’s resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company’s assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Allergan PLC, Consolidated Statement of Financial Position, Liabilities and Stockholders’ Equity

USD $ in thousands

		Dec 31, 2017		Dec 31, 2016		Dec 31, 2015		Dec 31, 2014		Dec 31, 2013
	Accrued third-party rebates
	Contractual commitments, including amount due to Teva
	Accrued payroll and related benefits
	Accrued returns
	Interest payable
	Royalties payable
	Accrued pharmaceutical fees
	Accrued R&D expenditures
	Accrued severance, retention and other shutdown costs
	Litigation-related reserves and legal fees
	Accrued non-provision taxes
	Current portion of contingent consideration obligations
	Accrued selling and marketing expenditures
	Dividends payable
	Other accrued expenses
	Accrued expenses
	Accounts payable
	Accounts payable and accrued expenses
	Income taxes payable
	Current portion of long-term debt and capital leases
	Deferred revenue
	Current liabilities held for sale
	Deferred tax liabilities
	Current liabilities
	Long-term debt and capital leases, excluding current portion
	Acquisition related contingent consideration liabilities
	Long-term pension and post retirement liability
	Legacy Allergan deferred executive compensation
	Long-term severance and restructuring liabilities
	Deferred revenue
	Product warranties
	Long-term contractual obligations
	Litigation-related reserves
	Other long-term liabilities
	Other long-term liabilities
	Long-term liabilities held for sale
	Other taxes payable
	Deferred tax liabilities
	Non current liabilities
	Total liabilities
	Preferred shares, $0.0001 par value per share
	Ordinary shares; $0.0001 par value per share
	Additional paid-in capital
	Retained earnings (accumulated deficit)
	Accumulated other comprehensive income (loss)
	Treasury stock, at cost
	Shareholders’ equity
	Noncontrolling interest
	Total equity
	Total liabilities and equity

Based on: 10-K (filing date: 2018-02-16), 10-K (filing date: 2017-02-24), 10-K (filing date: 2016-02-26), 10-K (filing date: 2015-02-18), 10-K (filing date: 2014-02-25).

Item	Description	The company
Current liabilities	Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.	Allergan PLC’s current liabilities declined from 2015 to 2016 but then increased from 2016 to 2017 exceeding 2015 level.
Non current liabilities	Amount of obligation due after one year or beyond the normal operating cycle, if longer.	Allergan PLC’s non current liabilities declined from 2015 to 2016 and from 2016 to 2017.
Total liabilities	Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.	Allergan PLC’s total liabilities declined from 2015 to 2016 and from 2016 to 2017.
Shareholders’ equity	Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity’s stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.	Allergan PLC’s shareholders’ equity declined from 2015 to 2016 and from 2016 to 2017.

	Allergan PLC	Other companies (not purchased previously)
Financial Statements
Common-Size Financial Statements
Ratios
Relative Valuation
Discounted Cash Flow (DCF) Valuation
Economic Value Added (EVA)
Long-term Trends
Analysis
Financial Reporting Quality

	All companies
Financial Statements
Common-Size Financial Statements
Ratios
Relative Valuation
Discounted Cash Flow (DCF) Valuation
Economic Value Added (EVA)
Long-term Trends
Analysis
Financial Reporting Quality